
The episode discusses advancements in small molecule drug discovery and the role of AI, featuring insights from Genesis Molecular AI co-founders.
This episode has a fun personal twist: There’s a counterfactual world where I was employee #1 at Genesis Molecular AI , the company behind today’s episode. A certain introduction happened a few weeks too late and I had already happily signed at Atomwise, another ML-for-drug-discovery startup. Same problem, different company. I was certain ML was going to transform small molecule drug discovery. Early results were underwhelming. Useful at times, but nowhere near revolutionary. In the last year I’ve seen signs that ML is finally ready to deliver on my convictions from a decade ago. Genesis is one of the places that might have finally cracked this problem. I was super excited to come full circle and catch up with co-founder Evan Feinberg and CTO Sergey Edunov . If you are at all interested in small molecule drug discovery, we think you will find this fascinating! In our nearly two hour chat we cover: * What is small molecule drug discovery, and why is it hard * Structure prediction as a hotbed of innovation in AI algorithms * How advances in AI elsewhere have enabled stepwise improvements in predictive power * How the community benchmarks are essentially calling AI slop good enough…
Explore listener stats, chart rankings, contacts and more on the Latent Space: The AI Engineer Podcast podcast page.